NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $18.99 +0.60 (+3.26%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$19.10 +0.11 (+0.60%) As of 09/18/2026 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Greenwich LifeSciences Stock (NASDAQ:GLSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Greenwich LifeSciences alerts:Sign Up Key Stats Today's Range$18.25▼$20.0450-Day Range$12.77▼$19.5452-Week Range$7.78▼$34.10Volume302,252 shsAverage Volume116,367 shsMarket Capitalization$278.77 millionP/E RatioN/ADividend YieldN/APrice Target$69.00Consensus RatingHold Company Overview Greenwich LifeSciences, Inc. is a clinical-stage biotechnology company focused on developing cancer immunotherapies. The company’s lead product candidate is nelipepimut-S (NPS), a peptide-based immunotherapy designed to stimulate an immune response against HER2/neu, a protein expressed in several types of cancer. Greenwich LifeSciences has primarily studied NPS as an adjuvant treatment for patients with HER2-expressing breast cancer, including in combination with trastuzumab. Its clinical development program has included the Phase III PRESENT trial, which evaluated NPS in patients with early-stage breast cancer who had completed standard surgery and other indicated treatments. NPS remains an investigational therapy and is not an approved commercial product. The company was founded to advance NPS-based cancer treatments and is headquartered in Houston, Texas. Greenwich LifeSciences is led by Chief Executive Officer Snehal Patel, who has been associated with the company since its formation. Its activities have centered on clinical research and development in the United States, with no broad commercial product portfolio publicly identified.AI Generated. May Contain Errors. Read More Greenwich LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreGLSI MarketRank™: Greenwich LifeSciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 600th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingGreenwich LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialGreenwich LifeSciences has a consensus price target of $69.00, representing about 263.3% upside from its current price of $18.99.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 2 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Greenwich LifeSciences are expected to grow in the coming year, from ($1.38) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -12.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -12.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 633.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Greenwich LifeSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.32% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 11.35, which indicates bearish sentiment.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 4.22%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. News and Social Media1.1 / 5News SentimentN/A News SentimentGreenwich LifeSciences has a news sentiment score of -1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Greenwich LifeSciences this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Greenwich LifeSciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.6 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $76,618.00 in company stock, which represents 0.0275% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $76,618.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders51.47% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLSI Stock News Headlines3 Clinical-Stage Cancer Stocks With Pristine Balance SheetsSeptember 16 at 4:35 AM | finance.yahoo.comGreenwich LifeSciences Extends Insider and Pre-IPO Share Lock-Up to January 31, 2027August 10, 2026 | quiverquant.comQThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.September 19 at 1:00 AM | Banyan Hill Publishing (Ad)Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027August 10, 2026 | globenewswire.comGreenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer TrialJuly 22, 2026 | quiverquant.comQGreenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United KingdomJuly 22, 2026 | globenewswire.comGreenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial OutlookJuly 20, 2026 | quiverquant.comQGreenwich LifeSciences Provides Clinical Updates on FLAMINGO-01July 20, 2026 | globenewswire.comSee More Headlines GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $21.01 at the beginning of the year. Since then, GLSI shares have decreased by 9.6% and is now trading at $18.99. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) released its earnings results on Tuesday, August, 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.06. When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $8 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,260,870 shares at a price of $5.75-$6.75 per share. Aegis Capital served as the underwriter for the IPO. Who are Greenwich LifeSciences' major shareholders? Greenwich LifeSciences' top institutional investors include BlackRock Inc. (3.31%), Bank of New York Mellon Corp (0.33%), GSA Capital Partners LLP (0.13%) and Ancora Advisors LLC (0.07%). Insiders that own company stock include Snehal Patel and Jaye Thompson. View institutional ownership trends. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Greenwich LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/11/2026Today9/19/2026Next Earnings (Estimated)11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 GLSI's financial health is in the Red zone, according to TradeSmith. GLSI has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GLSI CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees13Year Founded2006Price Target and Rating Average Price Target for Greenwich LifeSciences$69.00 High Price Target$69.00 Low Price Target$69.00 Potential Upside/Downside+263.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$19.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-793.81% Return on Assets-295.32% Debt Debt-to-Equity RatioN/A Current Ratio1.54 Quick Ratio1.54 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book633.00Miscellaneous Outstanding Shares14,680,000Free Float7,123,000Market Cap$278.77 million OptionableNot Optionable Beta1.47 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:GLSI) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLSI Stock Alerts